Advances in neurodegenerative diagnostics
Explore the latest tools and breakthroughs transforming neurodegenerative disease diagnostics
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and ALS are progressive and incurable, leading to the gradual loss of neuronal function and structure. These conditions profoundly impact cognition, movement, and quality of life, posing challenges not only for patients but also for families, communities, and healthcare systems worldwide. As the global population ages, the need for earlier and more accurate diagnosis has become increasingly urgent.
Recent advances in biomedical research, data science, and diagnostic technologies are shedding new light on the biological complexity of these diseases. Innovations such as real-time brain imaging, blood-based biomarkers, digital diagnostics, and artificial intelligence are ushering in a new era of neurodegenerative diagnostics. These tools offer powerful new capabilities for early detection, patient stratification, and the development of personalized treatment strategies.
In this feature, we explore the forefront of neurodegenerative diagnostics, from cutting-edge imaging techniques and biomarker breakthroughs to genetic profiling and precision medicine. Gain expert insights into the innovations driving earlier diagnoses, more targeted therapies, and improved outcomes for patients affected by these devastating conditions.
Master ELISA for complex neurological samples
Discover expert guidance on assay formats, antibody validation, and signal amplification, plus protocols, selection strategies, and troubleshooting tips for accurate detection of biomarkers in CSF and other complex samples.
Download resource
Epigenetic analysis of 6-base genome in Parkinson’s disease
The emergence of the ‘6-base genome’, which includes the modified bases 5-methylcytosine (5mC) and its oxidised form, 5-hydroxymethylcytosine (5hmC), marks a significant evolution in our understanding of genetic and epigenetic regulation. In this webinar, Burleen Chhatwal from University College London, UK, demonstrates how biomodal’s 6-base genome supported the successful analysis of both 5mC and 5hmC modifications in Parkinson’s disease compared to controls in a pilot study.
Watch video
First FDA-cleared blood test to aid Alzheimer’s-linked amyloid pathology detection
Fujirebio’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test is the first FDA-cleared blood-based IVD in the U.S. to aid in identifying amyloid pathology associated with Alzheimer’s disease. This automated, minimally invasive assay provides a reliable tool for early assessment in patients with cognitive decline.
Read article
Advances in biomarker diagnostics for Alzheimer’s disease
Revvity’s Euroimmun shares expert insights into the role of core and emerging biomarkers, such as amyloid-beta, tau, NfL, and APOE genotype, in identifying Alzheimer's disease pathology and supporting differential diagnosis. Learn how advanced detection methods, including chemiluminescence immunoassays, ELISAs, and real-time PCR, are driving more precise, scalable, and personalized diagnostic strategies to improve patient outcomes.
Read article
